Please login to the form below

Not currently logged in
Email:
Password:

Strattera

This page shows the latest Strattera news and features for those working in and with pharma, biotech and healthcare.

Lilly axes 3,500 jobs in $500m-a-year cost-cutting drive

Lilly axes 3,500 jobs in $500m-a-year cost-cutting drive

Strattera (atomoxetine) and erectile dysfunction therapy Cialis (tadalafil).

Latest news

  • Shire launches long-acting ADHD drug Intuniv in UK Shire launches long-acting ADHD drug Intuniv in UK

    It is also the first alternative to Eli Lilly's non-stimulant ADHD therapy Strattera (atomoxetine) in Europe, providing another option for the approximately 10% of people with the condition who

  • Lilly feels effects of Cymbalta competition Lilly feels effects of Cymbalta competition

    to $588m and attention-deficit hyperactivity disorder (ADHD) drug Strattera (atomoxetine) brought in $201m, up 23 per cent.

  • Scotland first in UK to back Pfizer's Inlyta Scotland first in UK to back Pfizer's Inlyta

    month - along with Roche's Lucentis (ranibizumab) for pathologic myopia and Eli Lilly's attention deficit hyperactivity disorder (ADHD) therapy Strattera (atomoxetine).

  • Lilly’s Strattera wins new adult ADHD licence in UK Lilly’s Strattera wins new adult ADHD licence in UK

    Adults in the UK with attention deficit hyperactivity disorder (ADHD) who were not prescribed medicine as a child will now have access to Lilly's Strattera after it was approved by ... Strattera's new licence is backed by results from clinical trials

  • Lilly's Strattera patent upheld in US

    The US court of appeals has upheld the validity of Eli Lilly &Company's patent for ADHD drug Strattera. ... However, the most recent decision upholds Lilly's method-of-use patent which provides protection for Strattera until May, 2017.

More from news
Approximately 1 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Challenging perceptions Challenging perceptions

    These classes were methylphenidate-based products like Johnson &Johnson's Concerta (methylphenidate hydrochloride) and Lilly's non-stimulant Strattera (atomoxetine).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....